Quince Therapeutics announced that Directors June Bray, David Lamond, and Christopher Senner tendered conditional resignations effective after the Special Meeting of Stockholders on October 6, 2026. The resignations are contingent upon stockholder approval of three proposals: converting Series C Preferred Stock and exercising related warrants (potentially representing over 20% of outstanding shares), approving a private placement for conversion proceeds under Nasdaq Rule 5635(d), and increasing authorized common stock from 250 million to 275 million. Concurrently, the Board conditionally appointed Catherine Bonuccelli, Leone Patterson, James Valentine, and Drayton Wise as new directors effective upon approval of these proposals. The company operates in the biopharmaceutical industry.
